GlassScriptPhysician profile
Benjamin Scott Dieter
NPI 1538352968
$7,263.96
in general payments reported to CMS, 2019-2025
57 companies · $758 in 2025
The $758 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,483 · 2020: $1,020 · 2021: $1,332 · 2022: $742 · 2023: $1,000 · 2024: $928 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,686.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,566.05 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $681.14 | 2020-2025 | Ubrelvy, Vraylar, Liletta |
| Pfizer INC. | $603.24 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $574.84 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Supernus Pharmaceuticals, INC. | $520.00 | 2019-2020 | |
| Amgen INC. | $470.40 | 2019-2024 | Enbrel, Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $447.57 | 2019-2024 | |
| Lilly USA, LLC | $379.40 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $208.09 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| E.R. Squibb & Sons, L.L.C. | $130.90 | 2020-2022 | |
| Astellas Pharma US INC | $101.28 | 2019-2025 | Veozah |
| Corcept Therapeutics | $92.19 | 2024-2025 | Korlym |
| Mylan Specialty L.P. | $89.39 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.65 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.78 | 2023 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Dieter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.